GFA
REGN icon

Gallagher Fiduciary Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-263
Closed -$276K – 303
2024
Q3 		$276K Sell
263
-8
-3% -$8.9K 0.06% 212
2024
Q2 		$285K Buy
271
+9
+3% +$8.72K 0.06% 168
2024
Q1 		$252K Sell
262
-12
-4% -$11.4K 0.01% 163
2023
Q4 		$241K Buy
+274
New +$226K 0.01% 164

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gallagher Fiduciary Advisors's REGN Position: Q4 2024 in Review

Gallagher Fiduciary Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 263 shares — an estimated $276K sold.

Gallagher Fiduciary Advisors first reported a position in REGN in Q4 2023 and held it in 4 quarters. The position peaked at $285K in Q2 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Gallagher Fiduciary Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Gallagher Fiduciary Advisors sold 263 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $276K.
  • Gallagher Fiduciary Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Gallagher Fiduciary Advisors's Regeneron Pharmaceuticals position peaked at $285K in Q2 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Gallagher Fiduciary Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.